Overview
Tomoko Matsushima practices practicing medicine in Kobe, Japan.
Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Colorectal Cancer, and Breast Cancer.
She is actively involved in clinical research, co-authoring 13 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Tomoko Matsushima
Is Tomoko Matsushima a top-rated expert for Renal Cell Carcinoma (RCC)?
MediFind is an objective health platform that identifies experts based on real-world data. Tomoko Matsushima is classified as an Experienced expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Tomoko Matsushima participate in research or clinical trials?
Yes. Tomoko Matsushima has published 13 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Tomoko Matsushima's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Breast CancerMs. Matsushima isExperienced. Learn about Breast Cancer.
- Colorectal CancerMs. Matsushima isExperienced. Learn about Colorectal Cancer.
- Renal Cell Carcinoma (RCC)Ms. Matsushima isExperienced. Learn about Renal Cell Carcinoma (RCC).